SYMBIOSIS Pharmaceutical Services has appointed Dr. Thomas Scullion as a U.S. business development manager to aid the company’s growing commercial interests and client relationships in North America for sterile manufacturing.
  
Dr. Scullion previously worked in business development for the a large drug discovery CRO. He has spent the majority of his career working within the life science industry across both the public and private sectors.
 
Colin MacKay, chief executive officer at Symbiosis Pharmaceutical Services, said, “North America continues to be the strongest area of growth for our business so it is essential that we have the best expertise and a sufficient resource in place to drive opportunities for commercial development alongside managing existing relationships in this key territory.
 
“Many U.S. companies undertaking clinical trials in the EU are electing to use a GMP manufacturer who is based in that market, such as Symbiosis, to facilitate effective compliance with the QP requirements demanded for release of drug product for clinical trial use.  
 
“Thomas has an impressive track record and we expect he will bring great energy and strategic focus to his new role. Our reputation continues to grow in the outsourcing sector as the ‘go-to’ CMO for small-scale sterile filling and our newest recruit will proactively promote and reinforce this core message in the U.S.”